Intravascular AAV9 administration for delivering RNA silencing constructs to the CNS and periphery

Brett D. Dufour, Jodi McBride

    Research output: Chapter in Book/Report/Conference proceedingChapter

    3 Citations (Scopus)

    Abstract

    Viral vector delivery of RNA silencing constructs, when administered into vasculature, typically results in poor central nervous system (CNS) transduction due to the inability of the vector to cross the blood-brain barrier (BBB). However, adeno-associated virus serotype 9 (AAV9) has the ability to cross the BBB and robustly transduce brain parenchyma and peripheral tissues at biologically meaningful levels when injected intravenously. Recent work by our lab has shown that this method can be used to deliver RNA silencing constructs, resulting in signifi cant reductions in gene expression in multiple brain regions and in peripheral tissues. Here, we outline a method for delivery of AAV9 vectors expressing RNA interference (RNAi) constructs that lead to robust simultaneous transduction of mouse peripheral tissues and the CNS following a single injection into the jugular vein. Additionally, we outline methods for necropsy and immunofl uorescence to detect AAV9 transduction patterns in the rodent CNS following a vascular delivery.

    Original languageEnglish (US)
    Title of host publicationMethods in Molecular Biology
    PublisherHumana Press Inc.
    Pages261-275
    Number of pages15
    Volume1364
    DOIs
    StatePublished - 2016

    Publication series

    NameMethods in Molecular Biology
    Volume1364
    ISSN (Print)10643745

    Fingerprint

    Dependovirus
    RNA Interference
    Central Nervous System
    Blood-Brain Barrier
    Jugular Veins
    Brain
    Blood Vessels
    Rodentia
    Gene Expression
    Injections
    Serogroup

    Keywords

    • AAV9
    • Gene therapy
    • Jugular vein
    • RNAi
    • Systemic
    • Vascular

    ASJC Scopus subject areas

    • Molecular Biology
    • Genetics

    Cite this

    Dufour, B. D., & McBride, J. (2016). Intravascular AAV9 administration for delivering RNA silencing constructs to the CNS and periphery. In Methods in Molecular Biology (Vol. 1364, pp. 261-275). (Methods in Molecular Biology; Vol. 1364). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-3112-5_21

    Intravascular AAV9 administration for delivering RNA silencing constructs to the CNS and periphery. / Dufour, Brett D.; McBride, Jodi.

    Methods in Molecular Biology. Vol. 1364 Humana Press Inc., 2016. p. 261-275 (Methods in Molecular Biology; Vol. 1364).

    Research output: Chapter in Book/Report/Conference proceedingChapter

    Dufour, BD & McBride, J 2016, Intravascular AAV9 administration for delivering RNA silencing constructs to the CNS and periphery. in Methods in Molecular Biology. vol. 1364, Methods in Molecular Biology, vol. 1364, Humana Press Inc., pp. 261-275. https://doi.org/10.1007/978-1-4939-3112-5_21
    Dufour BD, McBride J. Intravascular AAV9 administration for delivering RNA silencing constructs to the CNS and periphery. In Methods in Molecular Biology. Vol. 1364. Humana Press Inc. 2016. p. 261-275. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-3112-5_21
    Dufour, Brett D. ; McBride, Jodi. / Intravascular AAV9 administration for delivering RNA silencing constructs to the CNS and periphery. Methods in Molecular Biology. Vol. 1364 Humana Press Inc., 2016. pp. 261-275 (Methods in Molecular Biology).
    @inbook{2036c38a8e6742de87910e99d9a730a2,
    title = "Intravascular AAV9 administration for delivering RNA silencing constructs to the CNS and periphery",
    abstract = "Viral vector delivery of RNA silencing constructs, when administered into vasculature, typically results in poor central nervous system (CNS) transduction due to the inability of the vector to cross the blood-brain barrier (BBB). However, adeno-associated virus serotype 9 (AAV9) has the ability to cross the BBB and robustly transduce brain parenchyma and peripheral tissues at biologically meaningful levels when injected intravenously. Recent work by our lab has shown that this method can be used to deliver RNA silencing constructs, resulting in signifi cant reductions in gene expression in multiple brain regions and in peripheral tissues. Here, we outline a method for delivery of AAV9 vectors expressing RNA interference (RNAi) constructs that lead to robust simultaneous transduction of mouse peripheral tissues and the CNS following a single injection into the jugular vein. Additionally, we outline methods for necropsy and immunofl uorescence to detect AAV9 transduction patterns in the rodent CNS following a vascular delivery.",
    keywords = "AAV9, Gene therapy, Jugular vein, RNAi, Systemic, Vascular",
    author = "Dufour, {Brett D.} and Jodi McBride",
    year = "2016",
    doi = "10.1007/978-1-4939-3112-5_21",
    language = "English (US)",
    volume = "1364",
    series = "Methods in Molecular Biology",
    publisher = "Humana Press Inc.",
    pages = "261--275",
    booktitle = "Methods in Molecular Biology",

    }

    TY - CHAP

    T1 - Intravascular AAV9 administration for delivering RNA silencing constructs to the CNS and periphery

    AU - Dufour, Brett D.

    AU - McBride, Jodi

    PY - 2016

    Y1 - 2016

    N2 - Viral vector delivery of RNA silencing constructs, when administered into vasculature, typically results in poor central nervous system (CNS) transduction due to the inability of the vector to cross the blood-brain barrier (BBB). However, adeno-associated virus serotype 9 (AAV9) has the ability to cross the BBB and robustly transduce brain parenchyma and peripheral tissues at biologically meaningful levels when injected intravenously. Recent work by our lab has shown that this method can be used to deliver RNA silencing constructs, resulting in signifi cant reductions in gene expression in multiple brain regions and in peripheral tissues. Here, we outline a method for delivery of AAV9 vectors expressing RNA interference (RNAi) constructs that lead to robust simultaneous transduction of mouse peripheral tissues and the CNS following a single injection into the jugular vein. Additionally, we outline methods for necropsy and immunofl uorescence to detect AAV9 transduction patterns in the rodent CNS following a vascular delivery.

    AB - Viral vector delivery of RNA silencing constructs, when administered into vasculature, typically results in poor central nervous system (CNS) transduction due to the inability of the vector to cross the blood-brain barrier (BBB). However, adeno-associated virus serotype 9 (AAV9) has the ability to cross the BBB and robustly transduce brain parenchyma and peripheral tissues at biologically meaningful levels when injected intravenously. Recent work by our lab has shown that this method can be used to deliver RNA silencing constructs, resulting in signifi cant reductions in gene expression in multiple brain regions and in peripheral tissues. Here, we outline a method for delivery of AAV9 vectors expressing RNA interference (RNAi) constructs that lead to robust simultaneous transduction of mouse peripheral tissues and the CNS following a single injection into the jugular vein. Additionally, we outline methods for necropsy and immunofl uorescence to detect AAV9 transduction patterns in the rodent CNS following a vascular delivery.

    KW - AAV9

    KW - Gene therapy

    KW - Jugular vein

    KW - RNAi

    KW - Systemic

    KW - Vascular

    UR - http://www.scopus.com/inward/record.url?scp=84944463338&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84944463338&partnerID=8YFLogxK

    U2 - 10.1007/978-1-4939-3112-5_21

    DO - 10.1007/978-1-4939-3112-5_21

    M3 - Chapter

    C2 - 26472457

    AN - SCOPUS:84944463338

    VL - 1364

    T3 - Methods in Molecular Biology

    SP - 261

    EP - 275

    BT - Methods in Molecular Biology

    PB - Humana Press Inc.

    ER -